FDA Approves Imlunestrant (Inluriyo) for ESR1-Mutated Metastatic Breast Cancer - OncoDaily FDA Approves Imlunestrant (Inluriyo) for ESR1-Mutated Metastatic Breast Cancer / Breast Cancer, Cancer research, EMBER-3 trial, ESR1, ESR1 mutation,

FDA Approves Imlunestrant (Inluriyo) for ESR1-Mutated Metastatic Breast Cancer

oncodaily.com/fda-approval...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Imlunestrant #Inluriyo #mBC #BreastCancer

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer - OncoDaily ESMO Breast 2025: Imlunestrant + abemaciclib shows PFS benefit in CDK4/6i-pretreated ER+/HER2- advanced breast cancer, per EMBER-3 data.

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER3 #ESMOBreast25 #BreastCancer #Imlunestrant #Abemaciclib

#Medsky #oncosky #pharmasky Among patients with ER+ve #Breastcancer, HER2-ve advanced
BC #imlunestrant led to significantly longer progression-free survival vs standard Tx with ESR1 mutations & #Imlunestrant - #abemaciclib improved progression-free survival vs #imlunestrant alone .

Imlunestrant + abemaciclib likely to become a new 2L treatment option for HR+/HER2- Metastatic breast cancer - OncoDaily Imlunestrant + abemaciclib likely to become a new 2L treatment option for HR+/HER2- Metastatic breast cancer / cancer, Imlunestrant, Komal Jhaveri, OncoDaily,

Imlunestrant + abemaciclib likely to become a new 2L treatment option for HR+/HER2- Metastatic breast cancer

@ptarantinomd.bsky.social
@breastcancerdoc.bsky.social

oncodaily.com/blog/imlunes...

#Cancer #Imlunestrant #OncoDaily #Oncology #Medicine #Health

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | NEJM Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (E...

Oral SERD #Imlunestrant in #EMBER3 is shifting the game! No need to check for ESR1 mutations when combined with #verzenio, as revealed by @breastcancerdoc.bsky.social at @sabcs.bsky.social Insightful discussion by @DrBurstein #BreastCancer #OncologyBreakthroughs

www.nejm.org/doi/full/10....

Lilly's Imlunestrant Shows Promising Results in Advanced Breast Cancer Treatment with Improved Survival Rates Recent studies reveal that Lilly's imlunestrant significantly enhances progression-free survival in ER+, HER2- breast cancer patients. The combination with Verzenio offers even better outcomes.

Lilly's Imlunestrant Shows Promising Results in Advanced Breast Cancer Treatment with Improved Survival Rates #USA #Indianapolis #Breast_Cancer #Imlunestrant #Verzenio